Judge To Keep J&J CEO Off Stand In Risperdal Case
By Matt Fair ( September 26, 2012, 8:45 PM EDT) -- A Pennsylvania state judge said Monday that he won't reconsider his order quashing testimony from Johnson & Johnson's CEO as part of litigation accusing a J&J subsidiary of marketing antipsychotic drug Risperdal for off-label use in children despite the risk of side effects....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.